Chloe WilsonFranco Baresi, AC Milan's legendary captain and one of football's all-time greatest defenders, died on 31 July 2026 at the age of 66 after a prolonged battle with pulmonary nodule disease. His passing came just a day after AC Milan was forced to issue a public statement denying viral online hoaxes about his death — a sign of how closely the football world had been watching his condition since he revealed his diagnosis in August 2025. For Australians, his story is more than a sporting tragedy. It is a timely reminder that pulmonary nodules — small, abnormal growths in the lung tissue — are far more common than most people realise, and that early specialist consultation can make a critical difference to outcomes.
The Condition That Claimed Football's Greatest Defender
In August 2025, Baresi disclosed that he had undergone surgery to remove a pulmonary nodule and commenced a course of immunotherapy — a treatment that uses the body's own immune system to target abnormal cells. He described the surgery as successful, and in November 2025 posted an uplifting message on social media: "Long live life," alongside photographs from his playing days. In February 2026, he carried the Olympic torch at San Siro during the Milan-Cortina 2026 Winter Games, describing the moment as the greatest emotion of his sporting life.
Yet the disease progressed. By late July 2026, AC Milan confirmed he was in a "delicate" condition. He died on the night of 30–31 July 2026, leaving behind a legacy as one of the most technically complete defenders the game has ever produced — and an unexpected spotlight on a medical condition that affects millions globally.
A pulmonary nodule is a small, round or oval growth in the lung, typically less than 3 cm in diameter. The vast majority — around 95% — are benign, caused by past infections, inflammation, or scar tissue. However, a small proportion can represent early-stage lung cancer, and distinguishing between the two requires specialist evaluation. The critical challenge is that pulmonary nodules almost never cause symptoms. They are discovered incidentally, during a chest X-ray or CT scan performed for another reason — or, increasingly, through targeted screening programs.
Australia's National Lung Cancer Screening Program: What You Need to Know
As of 1 July 2025, Australia launched the National Lung Cancer Screening Program (NLCSP), a landmark Commonwealth-funded initiative offering free low-dose CT (LDCT) scans to eligible Australians. The program targets a high-risk population: people aged 50 to 70 with a significant smoking history and no current symptoms of lung cancer. According to the Victorian Department of Health's lung cancer screening program, dedicated nodule clinics have been established to manage findings systematically and ensure consistent specialist follow-up across the country.
The early results have been significant. Approximately 37,000 LDCT scans were performed within the first five months of the program's rollout, and 426 of those — roughly 1 in 87 scans — were flagged as high-risk or very high-risk nodules requiring further investigation. These numbers underscore both the scale of undetected nodule burden in the Australian population and the value of systematic early detection.
For context, lung cancer is Australia's leading cause of cancer death, claiming around 9,000 lives annually. The five-year survival rate when lung cancer is detected at Stage I is above 70%. At Stage IV, it falls to below 10%. Early detection is not a minor clinical advantage — it can be the difference between a curative procedure and palliative care.
The Monitoring Framework: How Nodules Are Classified
Under the NLCSP's Nodule Management Protocol, radiologists classify nodules using the Lung-RADS (Lung CT Screening Reporting and Data System) framework, the same standardised scoring system used by leading cancer centres internationally. Understanding your Lung-RADS category is the first conversation to have with a specialist.
- Category 1: No nodules, or findings with a very low probability of malignancy. Routine annual screening continues.
- Category 2: Definitely benign features or very low probability. Annual LDCT follow-up.
- Category 3: Moderate probability (less than 5%). A follow-up scan in 3 to 6 months is recommended.
- Category 4: High suspicion for malignancy. Immediate specialist referral for biopsy, PET scan, or surgical evaluation.
Nodule size drives much of this classification. Nodules smaller than 6 mm carry very low malignancy risk and are monitored annually. Those between 6 and 8 mm require 3-to-6-month CT follow-up. Nodules above 8 mm trigger the most urgent clinical attention and are typically referred to a respiratory physician or thoracic surgeon without delay.
A Concrete Scenario: What Happens If Your Scan Comes Back Flagged
Consider the following situation. A 58-year-old former smoker in Western Sydney — who quit cigarettes five years ago after a 25-year habit — books into the NLCSP through their GP. Their low-dose CT scan returns flagged: a 7.2 mm solid nodule in the right upper lobe, classified as Lung-RADS Category 3, meaning a less than 5% probability of malignancy.
Under the protocol, this person will be scheduled for a follow-up LDCT in three to six months. If the nodule grows by more than 1.5 mm or increases in density on that follow-up scan, the classification escalates to Category 4 and triggers specialist referral for tissue biopsy or PET-CT imaging. If the nodule remains stable across two consecutive annual scans, it is reclassified as Category 2, and routine monitoring resumes.
Here is the if/then logic that matters most: if the nodule is caught at 7.2 mm and ultimately requires surgical removal, the procedure is typically a minimally invasive video-assisted thoracoscopic surgery (VATS) resection, with a median hospital stay of 3 to 4 days and a five-year survival rate above 90% for Stage I disease. If the same patient delays seeking care for three years and the nodule grows to 25 mm with lymph node involvement, treatment escalates to a Stage III intervention requiring concurrent chemotherapy and radiotherapy — and potentially immunotherapy, the same treatment path Franco Baresi followed in his final year. The difference in outcome, recovery burden, and quality of life between these two timelines is enormous. Acting on a 7.2 mm flagged nodule in 2026 is not an overreaction. It is the decision that determines which pathway you enter.
A respiratory physician is the specialist best placed to interpret your Lung-RADS classification, advise on follow-up intervals, and coordinate further investigation if needed. ExpertZoom connects Australians with qualified health professionals who can answer these questions directly, often without the long waits associated with the public hospital outpatient system.
Who Is Most at Risk in Australia?
While the NLCSP currently targets smokers aged 50 to 70, pulmonary nodules can appear in non-smokers and younger patients. Risk factors that increase the likelihood of a nodule being malignant include:
- Current or former smoking history — responsible for approximately 85% of lung cancer cases in Australia
- Age above 50 — nodule malignancy risk increases substantially with age
- Occupational exposure to asbestos, radon, or industrial carcinogens — a particular concern in Australia given the legacy of asbestos use in construction and mining through the 1980s
- A personal or family history of lung cancer or thoracic malignancy
- Nodule morphology — spiculated (irregular-edged) nodules and those with ground-glass opacity carry higher malignancy risk than smooth, solid nodules
A 7 mm nodule discovered in a 64-year-old construction worker with a 30-pack-year smoking history is a fundamentally different clinical picture from the same finding in a healthy 38-year-old non-smoker who had a chest CT after a minor car accident. Specialist interpretation of your individual risk profile is not optional — it is the core of good nodule management.
What to Ask a Specialist
If you have been told you have a pulmonary nodule — whether through NLCSP screening, an incidental imaging finding, or a targeted investigation — the most important first step is understanding your classification and what it means for your monitoring schedule.
Key questions to raise with a respiratory physician or GP specialist:
- What is the exact size and Lung-RADS category of my nodule?
- Is it solid, part-solid, or ground-glass in appearance, and how does that affect my risk?
- What is my personal probability of malignancy, accounting for my age, smoking history, and occupational exposures?
- What is my follow-up schedule, and what changes on the next scan would trigger escalation?
- Should I enrol in the NLCSP if I am currently eligible and not yet screened?
Franco Baresi defended with quiet precision, reading the game before it unfolded. The same instinct — anticipating the threat before it arrives — is exactly what lung screening asks of Australians. If you have risk factors, talk to a specialist before symptoms appear. That window of early action is the one advantage medicine can give you.
This article is for general information only and does not constitute medical advice. If you are concerned about a lung imaging finding or have risk factors for lung cancer, consult a qualified health professional.
